ArticleMaterials today. Bio2026
Black phosphorus nanosheet-promoted prodrug activation for enhanced cancer therapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor hypoxia-activated prodrugs possess great potential for cancer therapy. However, their therapeutic effects are still limited by several factors, including suboptimal conversion to the active pharmaceutical ingredient in complex tumor environments. Here, we demonstrate a strategy using black phosphorus nanosheets (BPNSs) to boost the activation and therapeutic effects of a tumor hypoxia-activated prodrug, banoxantrone dihydrochloride (AQ4N). BPNSs can facilitate the activation of AQ4N to a toxic anticancer drug through their degradation, which consumes oxygen and acidifies the surrounding environment, and their selective interaction with AQ4N under slightly acidic conditions, which can activate AQ4N. Moreover, the combination of BPNSs and AQ4N can result in synergistic anticancer effects as an additional benefit. Using the features of BPNSs, an enhanced cancer therapy without obvious toxic side effects was achieved using AQ4N in a mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.